Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma

Purpose: Urokinase (uPA) is expressed in a number of highly invasive malignancies including breast cancer. Because production of uPA is associated with breast cancer progression and can serve as a useful prognostic marker, the purpose of this study was to examine the role of uPA promoter methylation as an indicator of uPA production in breast cancer patients. Experimental Design: We examined the methylation status of the uPA promoter and the levels of uPA expression in normal human breast epithelial cells and several human breast cancer cells by bisulfite sequencing analysis and reverse transcription-PCR. We also analyzed the methylation status of the uPA promoter in surgical biopsy samples from patients with breast cancer of different grades, as determined by the Elston-Ellis histological grading system. Results: Expression of uPA mRNA was only detected in the highly invasive estrogen receptor-negative breast cancer cell lines, where the promoter was completely demethylated. In normal and low invasive breast cancer cells, the uPA promoter was methylated, resulting in lack of uPA mRNA expression. Analysis of biopsy samples showed that demethylation of the uPA promoter is associated with malignant transformation. Reverse transcription-PCR analysis revealed that this demethylation of the uPA promoter is directly associated with induction of uPA mRNA expression, which is well known to be associated with poor prognosis in breast cancer patients. Conclusions: This study indicated that uPA expression in breast cancer patients is under epigenetic control via methylation of its promoter. Determination of uPA promoter methylation can therefore serve as an early reliable indicator of uPA production in breast cancer patients.

[1]  J. Campos,et al.  A Darwinian Legacy to Understanding Human Infancy , 2003, Annals of the New York Academy of Sciences.

[2]  A. Makrigiannakis,et al.  Endometrial Pinopodes and Uterine Receptivity , 2003, Annals of the New York Academy of Sciences.

[3]  S. Rabbani,et al.  Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[5]  J. Groopman,et al.  DNA Methylation as a Cancer‐Specific Biomarker , 2003 .

[6]  B. Dunn.  Hypomethylation: One Side of a Larger Picture , 2003, Annals of the New York Academy of Sciences.

[7]  C. Plass,et al.  The Development of CpG Island Methylation Biomarkers Using Restriction Landmark Genomic Scanning , 2003, Annals of the New York Academy of Sciences.

[8]  PAWAN K. Jain.  Epigenetics: The Role of Methylation in the Mechanism of Action of Tumor Suppressor Genes , 2003, Annals of the New York Academy of Sciences.

[9]  P. Laird,et al.  Sensitive Detection of DNA Methylation , 2003, Annals of the New York Academy of Sciences.

[10]  T. Kalebic.  Epigenetic Changes: Potential Therapeutic Targets , 2003, Annals of the New York Academy of Sciences.

[11]  A. Hoffman,et al.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. , 2003, The Journal of clinical investigation.

[12]  J. Groopman,et al.  DNA methylation as a cancer-specific biomarker: from molecules to populations. , 2003, Annals of the New York Academy of Sciences.

[13]  D. Conte,et al.  p16INK4A Hypermethylation Detected by Fluorescent Methylation-specific PCR in Plasmas from Non-Small Cell Lung Cancer , 2002 .

[14]  Rui Henrique,et al.  Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. , 2002, Urology.

[15]  M. Szyf,et al.  Regulation of DNA Methylation in Human Breast Cancer , 2002, The Journal of Biological Chemistry.

[16]  M. Duffy.  Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .

[17]  J. Herman,et al.  Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. , 2002, Cancer research.

[18]  S. Rabbani,et al.  Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. , 2002, Cancer research.

[19]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[20]  N. Harbeck,et al.  Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[22]  M. Duffy.  Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. , 2001, Biochemical Society transactions.

[23]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[24]  M. Jo,et al.  Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. , 2001, Journal of cell science.

[25]  A. Mazar,et al.  The role of the plasminogen activation system in angiogenesis and metastasis. , 2001, Surgical oncology clinics of North America.

[26]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[27]  A. Feinberg,et al.  Cancer epigenetics takes center stage. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Baylin.  DNA methylation and epigenetic mechanisms of carcinogenesis. , 2001, Developments in biologicals.

[29]  N. Brünner,et al.  The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. , 2000, Cancer research.

[30]  J. Weinstein.  Pharmacogenomics--teaching old drugs new tricks. , 2000, The New England journal of medicine.

[31]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[32]  A. Mazar,et al.  A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  J. Foekens,et al.  The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Foekens,et al.  The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[36]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[37]  Y. Kohgo,et al.  Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. , 1999, Hepato-gastroenterology.

[38]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[39]  H. Miyake,et al.  Elevation of serum levels of urokinase‐type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer , 1999, The Prostate.

[40]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[41]  S. Rabbani,et al.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.

[42]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[43]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[44]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[45]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[47]  P. Verde,et al.  An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. , 1988, Nucleic acids research.

[48]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.